Biomarker Analysis in Bo21015, a Phase Ii Randomised Study of First-Line Bevacizumab (Bev) Combined with Carboplatin-Gemcitabine (Cg) or Carboplatin-Paclitaxel (Cp) in Patients (Pts) with Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer (Nscl